大葉大學圖書館 |

Non-biological complex drugs[electronic resource] :the science and the regulatory landscape /

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
杜威分類號:	615.19
書名/作者:	Non-biological complex drugs : the science and the regulatory landscape // edited by Daan J.A. Crommelin, Jon S. B. de Vlieger.
其他作者:	Crommelin, Daan J.A.
出版者:	Cham : : Springer International Publishing :, 2015.
面頁冊數:	ix, 390 p. : : ill., digital ;; 24 cm.
Contained By:	Springer eBooks
標題:	Nanomedicine.
標題:	Bioactive compounds.
標題:	Biomedicine.
標題:	Pharmaceutical Sciences/Technology.
標題:	Pharmaceutical technology.
ISBN:	9783319162416 (electronic bk.)
ISBN:	9783319162409 (paper)
內容註:	Introduction: Defining the position of Non-Biological Complex Drugs -- Polymeric micelles -- Liposomes: the science and the regulatory landscape -- Glatiramoids -- Iron carbohydrate complexes: characteristics and regulatory challenges -- Drug Nanocrystals -- Analytical methods for determining the size (distribution) in parenternal dispersions -- NBCD Pharmacokinetics and Bioanalytical Methods to Measure Drug Release -- Low Molecular Weight Heparins, Biological Drugs close to Non-Biological Complex Drugs -- Nanoparticle Albumin-Bound Anticancer Agents -- The EU regulatory landscape of Non-Biological Complex Drugs -- What did we learn? What can we expect in the future? Concluding remarks and outstanding issues.
摘要、提要註:	The rise of bio- and nano-technology in the last decades has led to the emergence of a new and unique type of medicine known as non-biological complex drugs (NBCDs). This book illustrates the challenges associated with NBCD development, as well as the complexity of assessing the effects of manufacturing changes on innovator and follow-on batches of NBCDs. It also touches upon proven marketing authorization requirements for biosimilars that could be effective in evaluating follow-on NBCDs, including a demonstration of control over the manufacturing process and a need for detailed physico-chemical characterization and (pre)clinical tests. This book is meant to be used for years to come as a standard reference work for the development of NBCDs. Moreover, this book aims to stimulate discussions and further our thinking to ensure that decisions regarding the approval of complex drugs are made with relevant scientific data on the table. .
電子資源:	http://dx.doi.org/10.1007/978-3-319-16241-6

Non-biological complex drugs[electronic resource] :the science and the regulatory landscape /
Non-biological complex drugsthe science and the regulatory landscape /[electronic resource] :edited by Daan J.A. Crommelin, Jon S. B. de Vlieger. - Cham :Springer International Publishing :2015. - ix, 390 p. :ill., digital ;24 cm. - AAPS advances in the pharmaceutical sciences series,v.202210-7371 ;. - AAPS advances in the pharmaceutical sciences series ;3..

Introduction: Defining the position of Non-Biological Complex Drugs -- Polymeric micelles -- Liposomes: the science and the regulatory landscape -- Glatiramoids -- Iron carbohydrate complexes: characteristics and regulatory challenges -- Drug Nanocrystals -- Analytical methods for determining the size (distribution) in parenternal dispersions -- NBCD Pharmacokinetics and Bioanalytical Methods to Measure Drug Release -- Low Molecular Weight Heparins, Biological Drugs close to Non-Biological Complex Drugs -- Nanoparticle Albumin-Bound Anticancer Agents -- The EU regulatory landscape of Non-Biological Complex Drugs -- What did we learn? What can we expect in the future? Concluding remarks and outstanding issues.

The rise of bio- and nano-technology in the last decades has led to the emergence of a new and unique type of medicine known as non-biological complex drugs (NBCDs). This book illustrates the challenges associated with NBCD development, as well as the complexity of assessing the effects of manufacturing changes on innovator and follow-on batches of NBCDs. It also touches upon proven marketing authorization requirements for biosimilars that could be effective in evaluating follow-on NBCDs, including a demonstration of control over the manufacturing process and a need for detailed physico-chemical characterization and (pre)clinical tests. This book is meant to be used for years to come as a standard reference work for the development of NBCDs. Moreover, this book aims to stimulate discussions and further our thinking to ensure that decisions regarding the approval of complex drugs are made with relevant scientific data on the table. .

ISBN: 9783319162416 (electronic bk.)

Standard No.: 10.1007/978-3-319-16241-6doiSubjects--Topical Terms:

342485
Nanomedicine.

LC Class. No.: RS380

Dewey Class. No.: 615.19

Non-biological complex drugs[electronic resource] :the science and the regulatory landscape /
LDR:02736nam a2200325 a 4500 001 439148
003 DE-He213
005 20160111111109.0
006 m d
007 cr nn 008maaau
008 160322s2015 gw s 0 eng d
020 $a 9783319162416 (electronic bk.)
020 $a 9783319162409 (paper)
024 7 $a 10.1007/978-3-319-16241-6 $2 doi
035 $a 978-3-319-16241-6
040 $a GP $c GP
041 0 $a eng
050 4 $a RS380
072 7 $a TDCW $2 bicssc
072 7 $a MED072000 $2 bisacsh
082 0 4 $a 615.19 $2 23
090 $a RS380 $b .N812 2015
245 0 0 $a Non-biological complex drugs $h [electronic resource] : $b the science and the regulatory landscape / $c edited by Daan J.A. Crommelin, Jon S. B. de Vlieger.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2015.
300 $a ix, 390 p. : $b ill., digital ; $c 24 cm.
490 1 $a AAPS advances in the pharmaceutical sciences series, $x 2210-7371 ; $v v.20
505 0 $a Introduction: Defining the position of Non-Biological Complex Drugs -- Polymeric micelles -- Liposomes: the science and the regulatory landscape -- Glatiramoids -- Iron carbohydrate complexes: characteristics and regulatory challenges -- Drug Nanocrystals -- Analytical methods for determining the size (distribution) in parenternal dispersions -- NBCD Pharmacokinetics and Bioanalytical Methods to Measure Drug Release -- Low Molecular Weight Heparins, Biological Drugs close to Non-Biological Complex Drugs -- Nanoparticle Albumin-Bound Anticancer Agents -- The EU regulatory landscape of Non-Biological Complex Drugs -- What did we learn? What can we expect in the future? Concluding remarks and outstanding issues.
520 $a The rise of bio- and nano-technology in the last decades has led to the emergence of a new and unique type of medicine known as non-biological complex drugs (NBCDs). This book illustrates the challenges associated with NBCD development, as well as the complexity of assessing the effects of manufacturing changes on innovator and follow-on batches of NBCDs. It also touches upon proven marketing authorization requirements for biosimilars that could be effective in evaluating follow-on NBCDs, including a demonstration of control over the manufacturing process and a need for detailed physico-chemical characterization and (pre)clinical tests. This book is meant to be used for years to come as a standard reference work for the development of NBCDs. Moreover, this book aims to stimulate discussions and further our thinking to ensure that decisions regarding the approval of complex drugs are made with relevant scientific data on the table. .
650 0 $a Nanomedicine. $3 342485
650 0 $a Bioactive compounds. $3 395483
650 1 4 $a Biomedicine. $3 463454
650 2 4 $a Pharmaceutical Sciences/Technology. $3 464319
650 0 $a Pharmaceutical technology. $3 218539
700 1 $a Crommelin, Daan J.A. $3 626784
700 1 $a Vlieger, Jon S. B. de. $3 626785
710 2 $a SpringerLink (Online service) $3 463450
773 0 $t Springer eBooks
830 0 $a AAPS advances in the pharmaceutical sciences series ; $v 3. $3 466100
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-16241-6
950 $a Biomedical and Life Sciences (Springer-11642)